Interplay of leucocyte–platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients
British Journal of Haematology · 2025
DOI: 10.1111/bjh.19779 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Rubén Osuna-Gómez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Group of Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain. Hauptthemen laut MEDLINE: Hydrazines, Pyrazoles, Purpura, Thrombocytopenic, Idiopathic, Benzoates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
Eltrombopag (ELT) is a thrombopoietin‐receptor agonist that stimulates platelet (PLT) production in patients with primary immune thrombocytopenia (ITP). One potential mechanism of ELT is modulating the inflammatory response by increasing PLTs binding to leucocytes. This study examined the effect of ELT on leucocyte–PLTs complexes in 38 ITP patients. Patients, predominantly females with a mean age of 59 years, underwent treatments like corticosteroids, intravenous immunoglobulin and splenectomy. Compared to healthy donors, ITP patients exhibited lower percentages of lymphocyte with bound PLTs, but similar monocyte‐ or neutrophil with bound PLTs. ELT treatment increased PLTs counts and all types of leucocyte with bound PLTs. Network analysis showed dynamic changes in leucocyte with bound PLTs relationships due to ELT. Machine learning indicated that higher percentages of monocytes with bound PLTs were linked to a better clinical response to ELT. A possible mechanism was an increased IL‐10 production in monocytes with bound PLTs from responder patients. This study provides insights into the immunological changes in ITP patients undergoing ELT and suggests potential predictive biomarkers for treatment response and disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Group of Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain.
- Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Hematology Department, Hospital del Mar, Barcelona, Spain.
- Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain.
- Hematology Department, Hospital de Granollers, Granollers, Spain.
- Hematology Department, Hospital Universitari Mutua Terrassa, Terrassa, Spain.
ORCID-Profile: Rubén Osuna-Gómez, Silvana Novelli, Silvia Vidal
Förderung
- Novartis
Zitieren
APA
Osuna-Gómez, R., Zamora, C., Novelli, S., Garcia-Pallarols, F., Rodriguez, Y., Domingo, A., Canet, M., Olivera, P., Mulet, M., Cantó, E., Valcarcel, D., Sanchez-Gonzalez, B., & Vidal, S. (2025). Interplay of leucocyte–platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients. British Journal of Haematology. https://doi.org/10.1111/bjh.19779
Vancouver
Osuna-Gómez R, Zamora C, Novelli S, Garcia-Pallarols F, Rodriguez Y, Domingo A, et al. Interplay of leucocyte–platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients. British Journal of Haematology. 2025. doi:10.1111/bjh.19779
BibTeX
@article{OsunaGmez2025,
author = {Osuna-Gómez, Rubén and Zamora, Carlos and Novelli, Silvana and Garcia-Pallarols, Francesc and Rodriguez, Yva and Domingo, Abel and Canet, Marta and Olivera, Pavel and Mulet, Maria and Cantó, Elisabet and Valcarcel, David and Sanchez-Gonzalez, Blanca and Vidal, Silvia},
title = {Interplay of leucocyte–platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.19779}
}
EUVIMED